CHERIE SHULER: Open Payments
NPI 1760062301 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,228 in 69 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $618 · 2025 $1,228
Food & beverage: $1,228
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $207 |
| ABBVIE INC. | 10 | $154 |
| Lilly USA, LLC | 12 | $145 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $124 |
| Novo Nordisk Inc | 4 | $60 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Amgen Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
Products named: MOUNJARO, Kerendia, AIRSUPRA, QULIPTA, FARXIGA, Auvelity, TRELEGY ELLIPTA, GVOKE HYPOPEN.
Industry payments across AL — which companies pay providers there.
